|
1
|
Wilson GK, Tennant DA and McKeating JA:
Hypoxia inducible factors in liver disease and hepatocellular
carcinoma: Current understanding and future directions. J Hepatol.
61:1397–1406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao J, Du F, Shen G, Zheng F and Xu B:
The role of hypoxia inducible factor 2 in digestive system cancers.
Cell Death Dis. 6:e16002015. View Article : Google Scholar
|
|
3
|
Cuninghame S, Jackson R and Zehbe I:
Hypoxia inducible factor 1 and its role in viral carcinogenesis.
Virology. 456:457370–383. 2014.
|
|
4
|
Li S, Li Q, Yu W and Xiao Q: High glucose
and/or high insulin affects HIF 1 signaling by regulating AIP1 in
human umbilical vein endothelial cells. Diabetes Res Clin Pract.
109:48–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu LP, Hu BG, Ye C, Ho RL, Chen GG and
Lai PB: HBx mutants differentially affect the activation of hypoxia
inducible factor 1alpha in hepatocellular carcinoma. Br J Cancer.
110:1066–1073. 2014. View Article : Google Scholar :
|
|
6
|
Semenza GL: Hypoxia inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu C, Liu X, Wang S, Yan X, Tang Z, Wu K,
Li Y and Liu F: Hepatitis C virus core protein induces hypoxia
inducible factor 1α-mediated vascular endothelial growth factor
expression in Huh7.5.1 cells. Mol Med Rep. 9:2010–2014.
2014.PubMed/NCBI
|
|
8
|
Guerrieri F, Belloni L, Pediconi N and
Levrero M: Molecular mechanisms of HBV associated
hepatocarcinogenesis. Semin Liver Dis. 33:147–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui H, Li QL, Chen J, Na Q and Liu CX:
Hepatitis B virus X protein modifies invasion, proliferation and
the inflammatory response in an HTR 8/SVneo cell model. Oncol Rep.
34:2090–2098. 2015.PubMed/NCBI
|
|
10
|
Huang P, Zhuang B, Zhang H, Yan H, Xiao Z,
Li W, Zhang J, Tang Q, Hu K, Koeffler HP, et al: Hepatitis B virus
X protein (HBx) is responsible for resistance to targeted therapies
in hepatocellular carcinoma: Ex vivo Culture Evidence. Clin Cancer
Res. 21:4420–4430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ
and Wu C: The correlation of expression levels of HIF-1α and HIF-2α
in hepatocellular carcinoma with capsular invasion, portal vein
tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol.
44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun HX, Xu Y, Yang XR, Wang W-M, Bai H,
Shi R-Y, Nayar SK, Devbhandari RP, He Y, Zhu Q-F, et al: Hypoxia
inducible factor 2 alpha inhibits hepatocellular carcinoma growth
through the transcription factor dimerization partner 3/E2F
transcription factor 1 dependent apoptotic pathway. Hepatology.
57:1088–1097. 2013. View Article : Google Scholar :
|
|
13
|
Yang SL, Yu C, Jiang JX, Liu LP, Fang X
and Wu C: Hepatitis B virus X protein disrupts the balance of the
expression of circadian rhythm genes in hepatocellular carcinoma.
Oncol Lett. 8:2715–2720. 2014.PubMed/NCBI
|
|
14
|
Akahori H, Tsujino T, Naito Y, Sawada H,
Sugahara M, Fukui M, Ohyanagi M, Mitsuno M, Miyamoto Y and Masuyama
T: Nuclear factor-κB-hypoxia-inducible factor-2 pathway in aortic
valve stenosis. J Heart Valve Dis. 23:558–566. 2014.
|
|
15
|
Guan Z, Ding C, Du Y, Zhang K, Zhu JN,
Zhang T, He D, Xu S, Wang X and Fan J: HAF drives the switch of
HIF-1α to HIF-2α by activating the NFκB pathway, leading to
malignant behavior of T24 bladder cancer cells. Int J Oncol.
44:393–402. 2014.
|
|
16
|
Tian J, Yan J, Wang W, Zhong N, Tian L,
Sun J, Min Z, Ma J and Lu S: T-2 toxin enhances catabolic activity
of hypertrophic chondrocytes through ROS NFκB HIF-2α pathway.
Toxicol In Vitro. 26:1106–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoo YG, Cho S, Park S and Lee MO: The
carboxy terminus of the hepatitis B virus X protein is necessary
and sufficient for the activation of hypoxia inducible factor
1alpha. FEBS Lett. 577:121–126. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoo YG, Na TY, Seo HW, Seong JK, Park CK,
Shin YK and Lee M-O: Hepatitis B virus X protein induces the
expression of MTA1 and HDAC1, which enhances hypoxia signaling in
hepatocellular carcinoma cells. Oncogene. 27:3405–3413. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie H, Song J, Liu K, Ji H, Shen H, Hu S,
Yang G, Du Y, Zou X, Jin H, et al: The expression of hypoxia
inducible factor 1alpha in hepatitis B virus related hepatocellular
carcinoma: Correlation with patients prognosis and hepatitis B
virus X protein. Dig Dis Sci. 53:3225–3233. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen C and Kaelin WG Jr: The VHL/HIF axis
in clear cell renal carcinoma. Semin Cancer Biol. 23:18–25. 2013.
View Article : Google Scholar :
|
|
21
|
Gossage L, Eisen T and Maher ER: VHL, the
story of a tumour suppressor gene. Nat Rev Cancer. 15:55–64. 2015.
View Article : Google Scholar
|
|
22
|
Li M and Kim WY: Two sides to every story:
The HIF dependent and HIF independent functions of pVHL. J Cell Mol
Med. 15:187–195. 2011. View Article : Google Scholar :
|
|
23
|
Gambhir S, Vyas D, Hollis M, Aekka A and
Vyas A: Nuclear factor kappa B role in inflammation associated
gastrointestinal malignancies. World J Gastroenterol. 21:3174–3183.
2015.PubMed/NCBI
|
|
24
|
Bradford JW and Baldwin AS: IKK/nuclear
factor kappaB and oncogenesis: Roles in tumor initiating cells and
in the tumor microenvironment. Adv Cancer Res. 121:125–145. 2014.
View Article : Google Scholar
|
|
25
|
Fan H, Yan X, Zhang Y, Zhang X, Gao Y, Xu
Y, Wang F and Meng S: Increased expression of Gp96 by HBx induced
NF kappaB activation feedback enhances hepatitis B virus
production. PLoS One. 8:e655882013. View Article : Google Scholar
|
|
26
|
Liu Y, Lou G, Wu W, Shi Y, Zheng M and
Chen Z: Interferon-α sensitizes HBx expressing hepatocarcinoma
cells to chemotherapeutic drugs through inhibition of HBx mediated
NF-κB activation. Virol J. 10:1682013. View Article : Google Scholar
|
